<DOC>
	<DOCNO>NCT01840566</DOCNO>
	<brief_summary>The purpose study test safety deliver patient ' immune cell , call T cell , high-dose chemotherapy ( HDT ) autologous stem cell transplantation ( ASCT ) .</brief_summary>
	<brief_title>High Dose Therapy Autologous Stem Cell Transplantation Followed Infusion Chimeric Antigen Receptor ( CAR ) Modified T-Cells Directed Against CD19+ B-Cells Relapsed Refractory Aggressive B Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Transplant eligible patient eligible criterion meet per . Patients ≥ 18 year age aggressive Bcell nonHodgkin lymphoma subtypes include , relapse refractory diffuse large Bcell lymphoma ( DLBCL ) , transform follicular lymphoma meeting least one follow criterion : Bone marrow involvement time relapse refractory disease appropriate allogeneic transplantation . PET positive disease outside one radiation port unless singleport disease treat prior radiotherapy within port , follow &gt; = 2 cycle salvage chemotherapy , still achieve chemosensitive status 1999 IWG criterion ( section 12.2 12.383 ) . Creatinine ≤ 1.5 mg/100 ml ( measure 24 hour creatinine clearance ≥ 50 cc/min ) Bilirubin &lt; 2.0 mg/100 ml , AST ALT &lt; 3x upperlimit normal , PT PTT &lt; 2x normal outside set stable chronic anticoagulation therapy , Adequate cardiac function ( LVEF &gt; 40 % ) assess ECHO MUGA scan perform within 1 month treatment . Adequate pulmonary function assess DLCO &gt; = 45 % adjust hemoglobin . Life expectancy &gt; 3 month . Karnofsky performance status ≤ 70 ( see appendix VI ) . Patients aggressive Bcell malignancy include , limited : Burkitt lymphoma , transform CLL/SLL transform marginal zone lymphoma include 6.1 inclusion criterion . Patients previously treat autologous allogeneic bone marrow stem cell transplantation ineligible . Other past current malignancy unless opinion investigator contraindicate participation study . Uncontrolled bacterial , viral fungal infection . Patients HIV , active hepatitis B hepatitis C infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Autologous Stem Cell Transplantation</keyword>
	<keyword>HIGH DOSE CHEMOTHERAPY</keyword>
	<keyword>19-28z T cells/kg</keyword>
	<keyword>12-117</keyword>
</DOC>